Castle Biosciences Raises Full-Year Revenue Guidance After Strong Q1 Core Test Volume Growth
CSTL sits 70% above its 52-week low of $14.59 on elevated volume (1.8× avg).
Summary
Castle Biosciences reported improved Q1 2026 net loss and strong core test volume growth, leading to a raised full-year revenue guidance.
Key Events · Earnings and Guidance · CSTL
-
Q1 2026 Financial Results
Reported Q1 2026 revenue of $83.7 million and a net loss of $(14.5) million, significantly improving from a $(25.8) million net loss in Q1 2025.
-
Full-Year Guidance Raised
Increased 2026 total revenue guidance to $345-355 million, up from the prior range of $340-350 million, signaling management confidence.
-
Strong Core Test Volume Growth
Core revenue drivers, DecisionDx-Melanoma and TissueCypher, saw test report volumes increase by 16% and 58% year-over-year, respectively, contributing to a 36% overall increase in core test reports.
-
Solid Cash Position
Ended Q1 2026 with $261.7 million in cash, cash equivalents, and marketable investment securities, providing financial stability.
Analysis · CSTL · Industrial Applications And Services
Castle Biosciences reported Q1 2026 financial results, demonstrating a significant improvement in net loss to $(14.5) million, compared to $(25.8) million in Q1 2025 and better than the $24.2 million net loss reported for the full year 2025. While GAAP revenue slightly decreased year-over-year to $83.7 million, this was attributed to specific factors such as changes in Medicare coverage for DecisionDx-SCC and the discontinuation of IDgenetix. Crucially, the company's core revenue drivers, DecisionDx-Melanoma and TissueCypher, showed robust test volume growth of 16% and 58% respectively, leading to a 36% increase in total core test reports. Reflecting this operational momentum and management's confidence, the full-year 2026 revenue guidance was raised to $345-355 million, up from the previous $340-350 million. The company maintains a solid cash position of $261.7 million, providing financial flexibility despite higher net cash used in operations in Q1 due to one-time payouts.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CSTL was trading at $24.75 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $749.8M. The 52-week trading range was $14.59 to $44.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.